<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028327</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5141</org_study_id>
    <secondary_id>AACTG A5141</secondary_id>
    <secondary_id>A5161s</secondary_id>
    <secondary_id>A5162s</secondary_id>
    <nct_id>NCT00028327</nct_id>
  </id_info>
  <brief_title>Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care</brief_title>
  <official_title>Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Many HIV infected patients admitted to the intensive care area (ICA) have never taken&#xD;
      anti-HIV drugs. The purpose of this study is to learn whether starting anti-HIV drugs while&#xD;
      patients are in an ICA will help them to survive and get better faster. This study will also&#xD;
      evaluate patients who, though not in an ICA, have been admitted to the hospital for serious&#xD;
      illnesses or infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There has been considerable debate over the management of HIV infected individuals admitted&#xD;
      to the ICA. Mortality in HIV infected patients in the ICA correlates with the level of immune&#xD;
      suppression. The majority of HIV infected individuals entering the ICA are antiretroviral&#xD;
      naive. Despite the high mortality rates and the opportunity to intervene with antiretroviral&#xD;
      therapy, physicians do not routinely administer highly active antiretroviral therapy (HAART)&#xD;
      in the ICA. Early initiation of HAART, which improves immune function, could potentially&#xD;
      reduce mortality. Numerous studies have shown that there is a dramatic drop in the HIV-1 RNA&#xD;
      levels accompanied by an increase in the CD4 cell count within the first 2 to 4 weeks of&#xD;
      therapy. Sufficient data now exist that antiretrovirals could be administered in the ICA with&#xD;
      careful monitoring and attention to drug interactions. This study will evaluate the effect of&#xD;
      HAART in patients admitted to the hospital with an AIDS-defining illness, pneumonia, or&#xD;
      sepsis.&#xD;
&#xD;
      Upon entry into the study, patients are stratified according to a severity of illness score&#xD;
      (SAPS I) and CD4 cell count. Patients then are assigned to 1 of 2 study arms: Arm A: HAART&#xD;
      (lamivudine [3TC] and zidovudine [ZDV], or 3TC/ZDV, and nelfinavir [NFV] and efavirenz&#xD;
      [EFV]); or an alternative HAART for 4 weeks. Arm B: No antiretroviral regimen. Evaluations of&#xD;
      the following are performed: drug toxicity, immune status, viral load, arterial blood gas,&#xD;
      ventilator parameters, and evolution of the presenting illness. Pharmacokinetic trough&#xD;
      concentration analyses are performed on all patients in Arm A during 3 time points of their&#xD;
      illness. Patients are followed for 24 weeks after entry. Patients in Arm A may elect to&#xD;
      participate in two substudies. The first substudy will measure efavirenz and nelfinavir drug&#xD;
      levels in the blood to determine how critical illness affects pharmacokinetics. The second&#xD;
      substudy will evaluate the benefit of HAART in HIV infected patients being treated for&#xD;
      pneumocystis carinii pneumonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>250</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  CD4 cell count less than 350 cells/mm3 within 120 hours prior to study entry&#xD;
&#xD;
          -  Admission to an ICA (or to any part of the hospital with an arterial blood gas&#xD;
             PaO2/FiO2 ratio of &lt; 200 or SAPS I score &gt; 13) within 120 hours prior to study entry&#xD;
&#xD;
          -  Admitted to the hospital for sepsis, pneumonia, or other AIDS-defining disease&#xD;
&#xD;
          -  Acceptable methods of contraception&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Known resistance or intolerance to antiretroviral drugs that precludes use of an&#xD;
             effective HAART regimen of FDA approved drugs, excluding abacavir or full-dose&#xD;
             ritonavir&#xD;
&#xD;
          -  More than 7 days of HAART (a regimen of at least 3 drugs that includes a protease&#xD;
             inhibitor, a nonnucleoside reverse transcriptase inhibitor, or three nucleoside&#xD;
             analogues) within 4 weeks prior to study entry&#xD;
&#xD;
          -  Investigational drug within 14 days prior to study entry&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Allergy or sensitivity to any of the study drugs that cannot be substituted with&#xD;
             another drug&#xD;
&#xD;
          -  CNS mass lesion or bacterial meningitis&#xD;
&#xD;
          -  Certain medications&#xD;
&#xD;
          -  Uncertain availability for 6 month course of study&#xD;
&#xD;
          -  Require regular stomach suctioning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane Havlir</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Denis Jones</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univ School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1427</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>December 20, 2001</study_first_submitted>
  <study_first_submitted_qc>December 20, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2001</study_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2011</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Antiretroviral Therapy, Highly Active</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Intensive Care Units</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

